British drugmakers call for change to pricing regime

15 December 2022

The Association of the British Pharmaceutical Industry (ABPI) has warned UK lawmakers that an existing pricing agreement is unsustainable, and that the cost of agreed rebates are too high.

Originally agreed in 2019, the “Voluntary scheme for branded medicines pricing and access” (VPAS) requires manufacturers of branded medicines to offer a rebate, the cost of which has increased in recent years.

Next year, drugmakers will be required to return almost £3.3 billion ($4 billion) in sales revenue to the government, up from around £600 million in 2021 and £1.8 billion this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK